Jodi Russell
Family · Batesville, MSNPI 1144416504
Payments from drug & device makers
Across 122 payments — averaging $15.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$597
- Novo Nordisk$382
- AstraZeneca$177
- Abbott$133
- Boehringer Ingelheim$130
- Lilly USA, LLC$122
- plus $369 from 13 others
What the payments were for
- Food & beverage$1,910100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 48 | $597 |
| Novo Nordisk | 21 | $382 |
| AstraZeneca | 10 | $177 |
| Abbott | 6 | $133 |
| Boehringer Ingelheim | 8 | $130 |
| Lilly USA, LLC | 8 | $122 |
| Pfizer | 6 | $106 |
| Bayer | 2 | $41 |
| Shield Therapeutics Inc | 2 | $32 |
| GSK | 2 | $32 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Biohaven Pharmaceuticals, Inc. | 1 | $20 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $20 |
| Novartis | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Ironwood Pharmaceuticals, Inc | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
How this compares
$1,910 in reported general payments places this provider in the 80th percentile of 3,007 family providers in Mississippi.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 53 | $75,664 |
| TrulicityDulaglutide | 24 | $34,582 |
| JardianceEmpagliflozin | 31 | $29,331 |
| MounjaroTirzepatide | 22 | $23,364 |
| LinzessLinaclotide | 29 | $23,325 |
| EliquisApixaban | 11 | $19,343 |
| RexultiBrexpiprazole | 12 | $16,527 |
| BriviactBrivaracetam | 11 | $15,619 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $9,344 |
| Bydureon BciseExenatide Microspheres | 12 | $9,073 |
| XareltoRivaroxaban | 16 | $8,546 |
| Novolog FlexpenInsulin Aspart | 14 | $7,579 |
| Emgality PenGalcanezumab-Gnlm | 11 | $7,272 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 17 | $6,617 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $5,704 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $382 | $75,66453 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $122 | $57,94646 claims |
| Boehringer IngelheimJardiance | $130 | $29,33131 claims |
| AbbVieLinzess | $597 | $23,32529 claims |
| PfizerEliquis | $106 | $19,34311 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $177 | $12,46524 claims |
| GSKAnoro Ellipta | $32 | $5,70412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,007 family providers in Mississippi.
Other family in Batesville
- Cinda PerrymanFayette$888K
- Dodie McGeeRaymond$772K
- Gina BurgeJackson$237K
- Christy DavisJackson$208K
- Maranda EversollFlowood$197K
- Dana DelaskiJackson$158K
- Kristin CarrollJackson$158K
- Shannon FryeryOxford$127K
- Nativel CollinsMantachie$73K
- Ashley CocilovaFlowood$72K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.